AR089860A1 - Analogos de la grelina - Google Patents
Analogos de la grelinaInfo
- Publication number
- AR089860A1 AR089860A1 ARP130100293A ARP130100293A AR089860A1 AR 089860 A1 AR089860 A1 AR 089860A1 AR P130100293 A ARP130100293 A AR P130100293A AR P130100293 A ARP130100293 A AR P130100293A AR 089860 A1 AR089860 A1 AR 089860A1
- Authority
- AR
- Argentina
- Prior art keywords
- grelina
- analogs
- gastroparesis
- cachexia
- reperfusion
- Prior art date
Links
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 208000001288 gastroparesis Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000005027 intestinal barrier Anatomy 0.000 abstract 1
- 230000007358 intestinal barrier function Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- -1 method Chemical class 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Su uso médico, por ejemplo, en el tratamiento de la caquexia, de la enfermedad pulmonar obstructiva crónica, de diversos trastornos gastrointestinales (por ejemplo, la gastroparesis o los trastornos inflamatorios, tales como la colitis, la disfunción de la barrera intestinal o las lesiones por isquemia-reperfusión), de la pérdida de peso corporal o del apetito disminuido. Compuesto, método, molécula de ácido nucleico, vector, célula.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594970P | 2012-02-03 | 2012-02-03 | |
| US201261704393P | 2012-09-21 | 2012-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089860A1 true AR089860A1 (es) | 2014-09-24 |
Family
ID=47827139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100293A AR089860A1 (es) | 2012-02-03 | 2013-02-01 | Analogos de la grelina |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9657062B2 (es) |
| EP (1) | EP2809339A2 (es) |
| JP (1) | JP2015510505A (es) |
| AR (1) | AR089860A1 (es) |
| HK (1) | HK1204931A1 (es) |
| TW (1) | TW201336864A (es) |
| WO (1) | WO2013113916A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| JP6608383B2 (ja) * | 2014-03-04 | 2019-11-20 | モータス・セラピューティクス・インコーポレイテッド | Ｈ−Ｉｎｐ−（Ｄ）Ｂａｌ−（Ｄ）Ｔｒｐ−Ｐｈｅ−Ａｐｃ−ｎｈ２の液相合成方法およびその医薬的に許容される塩 |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| CN109627185A (zh) * | 2018-12-03 | 2019-04-16 | 吉尔生化（上海）有限公司 | 一种n-芴甲氧羰基-o-辛酰基-丝/苏氨酸的制备方法 |
| KR102593537B1 (ko) * | 2018-12-27 | 2023-10-26 | 삼성디스플레이 주식회사 | 구동 컨트롤러, 그것을 포함하는 표시 장치 및 표시 장치의 구동 방법 |
| WO2023161226A1 (en) | 2022-02-22 | 2023-08-31 | Pephexia Therapeutics Aps | Ghrelin agonists with improved potency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239364T3 (es) | 1996-09-09 | 2005-09-16 | Zealand Pharma A/S | Sintesis de peptidos en fase solida. |
| US5929035A (en) | 1998-04-14 | 1999-07-27 | Regents Of The University Of Michigan | Methods of treating intestinal disorders |
| JP5000848B2 (ja) * | 2002-05-21 | 2012-08-15 | 第一三共株式会社 | グレリン含有医薬組成物 |
| TWI325003B (en) | 2002-07-23 | 2010-05-21 | Sod Conseils Rech Applic | Ghrelin analogs |
| US7176292B2 (en) * | 2003-09-11 | 2007-02-13 | Dialean, Ltd. | Ghrelin variant protein |
| EP1524274B1 (en) | 2003-10-16 | 2008-03-05 | F. Hoffmann-La Roche Ag | Fluorescently labelled Ghrelin peptides. |
| WO2006058539A2 (en) * | 2004-11-30 | 2006-06-08 | Gastrotech Pharma A/S | Growth hormone secretagogue receptor 1a ligands |
| ES2474643T3 (es) | 2005-09-28 | 2014-07-09 | Ipsen Pharma | Análogos de grelina |
| CN103251933A (zh) | 2005-09-29 | 2013-08-21 | 益普生制药股份有限公司 | 用于刺激胃肠运动性的组合物和方法 |
| NZ576470A (en) | 2006-09-27 | 2012-09-28 | Ipsen Pharma Sas | Analogs of ghrelin substituted at the n-terminal |
-
2013
- 2013-02-01 AR ARP130100293A patent/AR089860A1/es unknown
- 2013-02-01 WO PCT/EP2013/052107 patent/WO2013113916A2/en active Application Filing
- 2013-02-01 EP EP13707563.6A patent/EP2809339A2/en not_active Withdrawn
- 2013-02-01 JP JP2014555237A patent/JP2015510505A/ja not_active Ceased
- 2013-02-01 US US14/376,088 patent/US9657062B2/en not_active Expired - Fee Related
- 2013-02-01 TW TW102104084A patent/TW201336864A/zh unknown
-
2015
- 2015-06-10 HK HK15105522.9A patent/HK1204931A1/xx unknown
-
2017
- 2017-04-12 US US15/485,401 patent/US20180009849A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015510505A (ja) | 2015-04-09 |
| HK1204931A1 (en) | 2015-12-11 |
| WO2013113916A3 (en) | 2013-11-21 |
| EP2809339A2 (en) | 2014-12-10 |
| US9657062B2 (en) | 2017-05-23 |
| US20150018518A1 (en) | 2015-01-15 |
| TW201336864A (zh) | 2013-09-16 |
| US20180009849A1 (en) | 2018-01-11 |
| WO2013113916A2 (en) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089860A1 (es) | Analogos de la grelina | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| EP2823043A4 (en) | HIGHLY CONCENTRATED ALPHA-GLUCOSIDASE COMPOSITIONS FOR THE TREATMENT OF MORBUS POMPE | |
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| WO2016081203A3 (en) | Phospholipid ether analogs as cancer-targeting drug vehicles | |
| PH12015501289A1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
| CU20130036A7 (es) | Triazina-oxidazoles | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| PE20180318A1 (es) | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA201490152A1 (ru) | Антагонисты trpm8 и их применение при лечении | |
| EA201300990A1 (ru) | Парентеральное введение тапентадола | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| IL245412A0 (en) | Polylinosinic-polycytidylic acid formulations for the treatment of upper respiratory tract infections | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| EP3377622A4 (en) | TARGETED DISTRIBUTION OF BIOVERCAPED THERAPEUTIC PROTEINS IN CROP CELLS TO CERTAIN CELL TYPES FOR THE TREATMENT OF DISEASES | |
| MX2019011265A (es) | Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2. | |
| CL2013000021A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable. | |
| CL2013002832A1 (es) | Compuestos derivados del acido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acetico, moduladores del receptor de prostaglandina d2; composicion farmaceutica; y uso en la prevencion y el tratamiento de enfermedades alergicas e inmunes tales como asma. | |
| EA201401045A1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
| EA201400786A1 (ru) | Карбоциклические нуклеозиды, их фармацевтическое применение и композиции | |
| MX2016011900A (es) | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |